What is William Blair’s Estimate for BMY Q1 Earnings?

Bristol-Myers Squibb (NYSE:BMY) – Research analysts at William Blair issued their Q1 2025 EPS estimates for shares of Bristol-Myers Squibb in a report issued on Monday, November 18th. William Blair analyst M. Phipps expects that the biopharmaceutical company will post earnings per share of $1.75 for the quarter. The consensus estimate for Bristol-Myers Squibb’s current full-year earnings is $0.93 per share. William Blair also issued estimates for Bristol-Myers Squibb’s Q2 2025 earnings at $1.92 EPS, Q3 2025 earnings at $2.04 EPS, Q4 2025 earnings at $1.80 EPS, FY2025 earnings at $7.51 EPS, FY2026 earnings at $7.19 EPS and FY2027 earnings at $7.46 EPS.

Several other analysts have also recently commented on the stock. UBS Group lifted their target price on shares of Bristol-Myers Squibb from $50.00 to $54.00 and gave the stock a “neutral” rating in a research note on Wednesday, October 9th. Morgan Stanley lifted their target price on shares of Bristol-Myers Squibb from $36.00 to $39.00 and gave the stock an “underweight” rating in a research note on Tuesday, November 12th. Daiwa Capital Markets raised shares of Bristol-Myers Squibb from a “neutral” rating to an “outperform” rating in a research note on Wednesday, November 13th. Leerink Partnrs raised shares of Bristol-Myers Squibb from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, November 12th. Finally, TD Cowen boosted their price objective on shares of Bristol-Myers Squibb from $53.00 to $59.00 and gave the company a “hold” rating in a research note on Monday, October 7th. Two equities research analysts have rated the stock with a sell rating, fourteen have given a hold rating, two have issued a buy rating and three have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Bristol-Myers Squibb presently has a consensus rating of “Hold” and a consensus price target of $54.07.

Bristol-Myers Squibb Trading Up 0.6 %

Shares of Bristol-Myers Squibb stock opened at $58.22 on Wednesday. The company has a debt-to-equity ratio of 2.83, a current ratio of 1.24 and a quick ratio of 1.09. Bristol-Myers Squibb has a 1 year low of $39.35 and a 1 year high of $61.08. The company has a market capitalization of $118.08 billion, a P/E ratio of -16.22, a P/E/G ratio of 15.62 and a beta of 0.44. The business has a 50 day moving average price of $53.46 and a 200 day moving average price of $47.61.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.49 by $0.31. Bristol-Myers Squibb had a positive return on equity of 11.94% and a negative net margin of 15.30%. The firm had revenue of $11.89 billion during the quarter, compared to the consensus estimate of $11.26 billion. During the same period in the previous year, the firm posted $2.00 EPS. The company’s quarterly revenue was up 8.4% compared to the same quarter last year.

Bristol-Myers Squibb Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, November 1st. Shareholders of record on Friday, October 4th were issued a $0.60 dividend. The ex-dividend date was Friday, October 4th. This represents a $2.40 dividend on an annualized basis and a yield of 4.12%. Bristol-Myers Squibb’s dividend payout ratio is currently -66.85%.

Insider Buying and Selling at Bristol-Myers Squibb

In related news, EVP Samit Hirawat purchased 1,830 shares of Bristol-Myers Squibb stock in a transaction dated Friday, November 1st. The shares were acquired at an average price of $54.67 per share, with a total value of $100,046.10. Following the completion of the transaction, the executive vice president now owns 62,109 shares of the company’s stock, valued at approximately $3,395,499.03. This trade represents a 3.04 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Phil M. Holzer sold 700 shares of the stock in a transaction dated Monday, November 4th. The stock was sold at an average price of $55.62, for a total transaction of $38,934.00. Following the transaction, the senior vice president now directly owns 11,760 shares in the company, valued at $654,091.20. The trade was a 5.62 % decrease in their position. The disclosure for this sale can be found here. 0.09% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Bristol-Myers Squibb

Large investors have recently made changes to their positions in the company. Bessemer Group Inc. grew its position in Bristol-Myers Squibb by 16.3% in the first quarter. Bessemer Group Inc. now owns 159,066 shares of the biopharmaceutical company’s stock worth $8,625,000 after buying an additional 22,286 shares during the last quarter. Lake Street Advisors Group LLC boosted its stake in Bristol-Myers Squibb by 54.7% in the 1st quarter. Lake Street Advisors Group LLC now owns 13,530 shares of the biopharmaceutical company’s stock worth $734,000 after purchasing an additional 4,784 shares during the period. Ossiam boosted its stake in Bristol-Myers Squibb by 31.7% in the 1st quarter. Ossiam now owns 88,183 shares of the biopharmaceutical company’s stock worth $4,782,000 after purchasing an additional 21,234 shares during the period. Payden & Rygel Investment Group acquired a new position in Bristol-Myers Squibb in the 1st quarter worth approximately $206,000. Finally, EntryPoint Capital LLC boosted its stake in Bristol-Myers Squibb by 113.0% in the 1st quarter. EntryPoint Capital LLC now owns 3,501 shares of the biopharmaceutical company’s stock worth $190,000 after purchasing an additional 1,857 shares during the period. Institutional investors and hedge funds own 76.41% of the company’s stock.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.